GCG and Obesity: However, novel dual receptor agonists have been developed for the treatment of obesity and T2D under the concept that GLP-1 restrains the hyperglycemic action of glucagon, while allowing it to exert its beneficial actions on bodyweight, food intake, lipid metabolism and thermogenesis (71).